アラート

NeoGenomics Inc. (NEO)

NasdaqCM: NEO · リアルタイム株価 · USD

16.16

+0.22 (1.38%)

終値時点： Aug 17, 2026, 3:59 PM

1.38% (1D)

買気配	11.57
時価総額	2.08B
売上高（TTM）	766.29M
純利益（TTM）	-51.88M
ベータ	1.73
EPS（TTM）	-0.4
PER（TTM）	n/a
予想PER	47.03
PBR（TTM）	2.63
PSR（TTM）	2.75
Earnings Date	Apr 29, 2025

売気配	20.14
出来高	1,118,084
平均出来高（20日）	2,773,137
始値	15.72
前日終値	15.94
当日レンジ	15.72 - 16.36
52週レンジ	5.94 - 16.92
アナリスト	Buy
目標株価	19 (17.57%)
配当	n/a
権利落ち日	n/a

NEOについて

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing se...

[続きを読む]

業種 Diagnostics & Research

セクター Healthcare

IPO日 Mar 16, 2004

従業員数 2,500

上場取引所 NasdaqCM

ティッカー NEO

ウェブサイト https://www.neogenomics.com

企業情報の全文

業績

2025年のNeoGenomicsの売上高は727.33Mで、前年の660.57Mから10.11%の増加でした。利益は-108.03Mで、37.22%の増加でした。

財務諸表

アナリスト予想

9件のアナリスト評価によると、NEO株の平均レーティングは「Buy」です。12か月後の目標株価は19で、直近株価から17.57%の上昇余地となります。

株価予想

決算サプライズ

NeoGenomicsはJul 28, 2026に四半期決算を発表しました：

売上高は $201.66M で、予想を下回りました $0, うち 11.21% の前年比増加にあたります.

EPSは 0.05 で、予想を上回りました 0.02, うち 66.67% の前年比増加にあたります.

次回決算発表

NeoGenomics Inc.の決算発表予定日は Apr 29, 2025, 寄り付き前の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

1週間前 · StockStory

3 Stocks Under $50 with Open Questions

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some ...

1週間前 · Simply Wall St.

NeoGenomics (NEO) Is Up 8.4% After Q2 Profit Return And Raised 2026 Outlook – Has The Bull Case Changed?

In July 2026, NeoGenomics, Inc. reported second-quarter 2026 results showing revenue of US$201.66 million and net income of US$2.24 million, compared with revenue of US$181.33 million and a net loss o...

1週間前 · Zacks

NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

2週間前 · Simply Wall St.

NeoGenomics (NEO) Following Q2 Profit And Raised Outlook, Is Fair Value Already Priced In?

NeoGenomics (NEO) is back in focus after second quarter earnings on 28 July 2026 reported quarterly profitability, revenue of US$201.66 million, and updated full year guidance that raised revenue expe...

2週間前 · StockStory

3 Healthcare Stocks with Questionable Fundamentals

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance bu...

2ページ中1ページ

NeoGenomics Inc. (NEO)